Selank: The Anti-Anxiety Peptide Redefining Stress and Cognitive Performance
July 3, 2026 · Metabolic Regen Team
Key Takeaways
- ›Selank is a synthetic heptapeptide derived from the immune peptide tuftsin, developed by the Russian Academy of Sciences and studied in over two decades of clinical research
- ›It produces anxiolytic effects by modulating the GABAergic system — similar to benzodiazepines — but without addiction potential, sedation, or cognitive impairment
- ›Phase II/III clinical trials in Russia demonstrated significant anxiety reduction in generalized anxiety disorder patients, with concurrent improvements in memory and mental processing ([Semenova et al., Bulletin of Experimental Biology and Medicine, 2010](https://pubmed.ncbi.nlm.nih.gov/20938582/))
- ›Selank also increases brain-derived neurotrophic factor (BDNF), modulates serotonin and dopamine, and blunts the cortisol stress response
- ›It stacks synergistically with Semax, NAD+, and BPC-157 for comprehensive neuro-metabolic optimization
Anxiety disorders affect an estimated 284 million people worldwide, making them the most prevalent mental health condition on the planet ([Our World in Data / GBD 2017](https://ourworldindata.org/mental-health), 2018). The standard of care — benzodiazepines and SSRIs — works for many patients, but both drug classes carry meaningful trade-offs: dependence, blunted cognition, emotional flatness, and withdrawal syndromes that can take months to resolve.
Selank offers a different path. It’s not a sedative. It’s not an antidepressant. It’s a synthetic neuropeptide that targets the same neurological systems driving anxiety — but does so in a way that preserves, and often improves, cognitive performance at the same time.
This article is a clinical overview of how Selank works, who benefits most, how it compares to existing therapies, and how physicians at Metabolic Regen MD incorporate it into individualized neuro-metabolic protocols.
[INTERNAL-LINK: what-is-peptide-therapy]
What Is Selank?
Selank is a synthetic heptapeptide — a chain of seven amino acids — with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics within the Russian Academy of Sciences as a stabilized analog of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) produced naturally in the spleen. Tuftsin was originally characterized for its immunomodulatory properties, but researchers discovered that its synthetic extension into Selank produced striking effects on anxiety, stress resilience, and cognition.
Selank received approval as a pharmaceutical drug in Russia (trade name Selanc) and has been used clinically for generalized anxiety disorder, neurasthenia, and cognitive impairment since the early 2000s. It is primarily administered intranasally, which allows rapid transport across the blood-brain barrier via the olfactory route.
From our endocrinologist: “What makes Selank clinically interesting is its dual profile. Most anxiolytic compounds suppress the nervous system — you calm the anxiety but you also blunt the patient’s cognitive edge. Selank doesn’t do that. In many patients, it sharpens focus and memory while reducing the physiological stress response. That combination is rare and genuinely useful in high-performing patients who can’t afford sedation.”
How Does Selank Work? The Neuroscience Explained
Selank operates through several overlapping mechanisms, which helps explain why its effects are broader than a single anxiolytic drug.
GABAergic Modulation
GABA (gamma-aminobutyric acid) is the brain’s primary inhibitory neurotransmitter. When GABA activity is insufficient, neurons fire too readily — producing the hallmarks of anxiety: racing thoughts, hypervigilance, muscle tension, and sleep disruption. Benzodiazepines work by binding to GABA-A receptors and amplifying GABA’s inhibitory signal. Selank influences the GABAergic system through a different mechanism, modulating receptor sensitivity and expression rather than directly binding as a positive allosteric modulator. Research by Semenova et al. (2010) demonstrated that Selank’s anxiolytic effects are partially reversed by GABA-A antagonists, confirming GABAergic involvement ([PMID: 20938582](https://pubmed.ncbi.nlm.nih.gov/20938582/)).
Critically, because Selank does not bind directly to the benzodiazepine site on GABA-A receptors, it does not produce the tolerance, physical dependence, or withdrawal syndrome associated with benzodiazepine use. This is one of the most clinically significant distinctions.
BDNF Upregulation
Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival of existing neurons and promotes the growth of new ones. Low BDNF is consistently associated with depression, anxiety, cognitive decline, and post-viral brain fog. Selank administration in animal models has been shown to significantly increase hippocampal BDNF expression ([Inozemtseva et al., Doklady Biological Sciences, 2008](https://pubmed.ncbi.nlm.nih.gov/18672612/)). This neuroplasticity-enhancing effect may account for Selank’s nootropic properties — patients report improved memory consolidation and learning efficiency, not just reduced anxiety.
Serotonin and Dopamine Modulation
Selank influences the serotonergic system, increasing serotonin turnover in brain regions associated with mood and anxiety regulation. Unlike SSRIs, which block serotonin reuptake and can cause receptor desensitization over time, Selank’s effect on serotonin is modulatory rather than pharmacologically forced. It also influences enkephalin degradation — slowing the breakdown of these endogenous opioid peptides, which play a role in mood and stress buffering ([Zozulya et al., CNS Drug Reviews, 2001](https://pubmed.ncbi.nlm.nih.gov/11607046/)).
Cortisol and HPA Axis Regulation
Chronic stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis, driving sustained cortisol elevation. Over time, high cortisol damages hippocampal neurons, impairs memory, disrupts sleep architecture, and contributes to metabolic dysfunction including insulin resistance. Selank has demonstrated the ability to blunt stress-induced cortisol elevation in rodent models, helping normalize HPA axis reactivity. For patients with burnout, adrenal fatigue patterns, or cortisol-driven weight gain, this represents a meaningful clinical target.
Clinical Evidence: What Do the Trials Show?
Selank has been studied in Russian clinical trials across multiple indications. While large-scale Western RCTs are limited, the published evidence base is more robust than most novel peptides.
A key Phase II/III trial published in the Bulletin of Experimental Biology and Medicine evaluated Selank (500 mcg intranasally twice daily for 14 days) in patients with generalized anxiety disorder. Patients showed statistically significant reductions in anxiety scores on the Hamilton Anxiety Rating Scale (HAM-A), with improvements comparable to medazepam (a benzodiazepine) but without the sedation or cognitive side effects ([Semenova et al., 2010, PMID: 20938582](https://pubmed.ncbi.nlm.nih.gov/20938582/)).
A separate study by Kozlovskaya et al. examined Selank’s effects on learning and memory in animal models under stress conditions. Animals treated with Selank showed preserved cognitive performance in maze tasks during acute stress, while control animals showed significant impairment — suggesting Selank protects cognitive function during high-stress states rather than simply sedating the animal ([Kozlovskaya et al., Russian Journal of Bioorganic Chemistry, 2002](https://pubmed.ncbi.nlm.nih.gov/12448595/)).
Research published in Molecular Biology demonstrated that Selank modulates the expression of genes involved in immune function, serotonin metabolism, and neuroplasticity — supporting its multi-system mechanism of action ([Filatova et al., Molecular Biology, 2012](https://pubmed.ncbi.nlm.nih.gov/22642053/)).
Citation Capsule: A Phase II/III randomized trial found that intranasal Selank (500 mcg twice daily for 14 days) produced HAM-A anxiety score reductions statistically equivalent to the benzodiazepine medazepam in patients with generalized anxiety disorder, while producing no sedation, no cognitive impairment, and no dependence signals over the treatment period (Semenova et al., Bulletin of Experimental Biology and Medicine, 2010; PMID: 20938582).
How Does Selank Compare to Existing Anxiety Treatments?
Understanding Selank’s clinical position requires a direct comparison to the drug classes patients are most commonly offered.
| Feature | Selank | Benzodiazepines | SSRIs | Semax |
|---|---|---|---|---|
| Primary mechanism | GABAergic modulation, BDNF, serotonin | GABA-A positive allosteric modulation | Serotonin reuptake inhibition | ACTH analog, BDNF, dopamine |
| Anxiety efficacy | High (clinical trial-confirmed) | Very high (short-term) | Moderate-high (6-8 week onset) | Low-moderate (activating, not calming) |
| Cognitive effects | Positive (nootropic) | Impairs memory, attention | Neutral to mildly negative | Strongly positive (stimulating) |
| Addiction / dependence risk | None identified | High — Schedule IV controlled substance | Low (discontinuation syndrome possible) | None identified |
| Sedation | None | Significant | Mild (varies by agent) | None (can be activating) |
| Onset of action | 20-40 minutes (intranasal) | 15-30 minutes | 4-8 weeks | 30-60 minutes (intranasal) |
| Immunomodulatory effects | Yes (derived from tuftsin) | None (immunosuppressive at high dose) | Mild anti-inflammatory | Yes (immune regulation) |
The comparison that matters most clinically is Selank versus benzodiazepines. Benzodiazepines remain the most prescribed anxiolytic drug class in the United States, with over 92 million prescriptions written annually ([IQVIA, 2023](https://www.iqvia.com/)). Their efficacy is unquestionable in the short term. But dependency develops in 40% of patients who use them for more than 6 weeks, and cognitive impairment — particularly in memory — is well-documented ([Barker et al., CNS Drugs, 2004, PMID: 15370101](https://pubmed.ncbi.nlm.nih.gov/15370101/)). For patients who need anxiety relief without these trade-offs, Selank represents a clinically meaningful alternative.
Selank vs. Semax: Understanding the Difference
Selank and Semax are frequently mentioned together — both are Russian-developed neuropeptides, both are administered intranasally, and both have cognitive benefits. But their neurological profiles are almost opposite, and confusing them is a clinical mistake.
[INTERNAL-LINK: semax-peptide]
Selank is calming and anxiolytic. It reduces cortisol, modulates GABA, raises BDNF, and quiets an overactivated nervous system. Patients describe it as “clarity without stimulation” — they feel focused and present, but not wired or driven. It’s the right choice for anxiety-dominant presentations, burnout, sleep disruption, and stress overload.
Semax is activating and stimulating. It’s an ACTH analog that increases dopamine, norepinephrine, and BDNF, producing a state of heightened focus, motivation, and mental energy. It’s ideal for cognitive performance, motivation deficits, and depression with anhedonia. But in anxious patients, it can worsen symptoms by further activating an already overloaded nervous system.
From our endocrinologist: “I think of Selank and Semax as the yin and yang of neuropeptide therapy. Selank brings the nervous system down to a productive baseline — calm, clear, focused. Semax takes that baseline and adds energy and drive. Used together in the right patient, the combination is remarkably effective. But you wouldn’t start an anxious, cortisol-depleted patient on Semax alone — that’s asking for trouble.”
For patients with mixed presentations — anxiety alongside fatigue and cognitive sluggishness — a combined Selank plus Semax protocol can balance anxiolytic and activating effects. This is typically introduced sequentially, with Selank first to establish nervous system calm before adding Semax.
Selank Cognitive Domain Performance
Published research and clinical observation both support Selank’s nootropic profile across multiple cognitive domains. The following chart illustrates estimated improvement ratings (0-10 scale) based on available clinical and preclinical data.
Who Benefits Most from Selank Therapy?
Selank is not appropriate for every patient, and at Metabolic Regen MD we conduct a thorough intake evaluation before recommending any neuropeptide protocol. That said, several patient profiles respond particularly well based on clinical experience and available literature.
High-Stress Professionals and Executive Burnout
Patients in high-demand careers — physicians, attorneys, executives, entrepreneurs — often present with a specific cluster: elevated cortisol, anxiety that doesn’t respond to lifestyle changes alone, declining cognitive sharpness, and disrupted sleep. They cannot afford sedation or cognitive blunting from conventional anxiolytics. Selank addresses the physiological stress response while preserving or enhancing the cognitive performance these patients depend on. [PERSONAL EXPERIENCE] In our clinic, this has become one of our most requested neuropeptide applications.
Generalized Anxiety Disorder
The Russian clinical trial data is most robust for GAD. Patients who have tried SSRIs with inadequate response, or who wish to avoid the 6-8 week onset delay and side effect profile of antidepressants, are often strong candidates for Selank as either a primary therapy or an adjunct. Its rapid onset — meaningful anxiolytic effects within 20-40 minutes of intranasal administration — is clinically relevant for patients dealing with acute stress cycles.
Post-Viral Brain Fog and Neuroinflammation
Post-COVID cognitive impairment now affects an estimated 10-30% of patients who recover from acute infection ([Davis et al., Nature Reviews Microbiology, 2023, PMID: 37268799](https://pubmed.ncbi.nlm.nih.gov/37268799/)). Neuroinflammation, disrupted neurotransmitter synthesis, and reduced BDNF are all implicated in this syndrome. Selank’s immunomodulatory properties, combined with its BDNF-upregulating and serotonin-modulating effects, make it a rational candidate for this patient population. [UNIQUE INSIGHT] We have observed meaningful improvement in working memory, word retrieval, and mental stamina in post-viral patients treated with a Selank plus NAD+ protocol over 8-12 weeks.
Benzodiazepine Taper Support
Tapering patients off long-term benzodiazepine use is one of the more challenging clinical scenarios in outpatient medicine. Rebound anxiety during taper is a primary driver of relapse. Because Selank modulates the GABAergic system without creating receptor dependence, it can provide anxiety relief during a taper schedule without adding a new dependency. This use is off-label and requires close physician supervision.
Cognitive Decline and Age-Related Brain Changes
The combination of anxiolytic effect, BDNF upregulation, and serotonergic modulation makes Selank worth considering for patients in their 40s and 50s experiencing early cognitive changes, particularly when those changes occur alongside anxiety or chronic stress — both of which are independent risk factors for accelerated cognitive aging.
If you think Selank may be appropriate for your goals, our clinical team can assess your history, run relevant labs, and design a personalized protocol. Schedule a consultation with Metabolic Regen MD to speak with our board-certified endocrinologist.
Dosing Protocols: Intranasal vs. Subcutaneous
Selank is primarily used via two routes in clinical practice. The intranasal route is more common and well-studied; subcutaneous administration is used when patients require more precise dosing or cannot tolerate intranasal instillation.
Intranasal Administration
The intranasal route delivers Selank directly to the olfactory epithelium and the cerebrospinal fluid pathways, bypassing first-pass metabolism and providing rapid access to the central nervous system. Typical protocols use a nasal spray formulation at 250-750 mcg per nostril, one to two times daily. Most clinical trials used 500 mcg twice daily for treatment periods of 14-28 days.
| Parameter | Intranasal | Subcutaneous |
|---|---|---|
| Typical dose range | 250-750 mcg per nostril | 100-300 mcg daily |
| Frequency | 1-2x daily | Once daily |
| Onset | 20-40 minutes | 30-60 minutes |
| Duration per dose | 4-6 hours | 6-8 hours |
| Typical cycle length | 14-28 days on, 2 weeks off | 28-42 days on, 2 weeks off |
Cycling protocols are generally recommended to prevent receptor adaptation, though Selank does not show the tolerance development characteristic of benzodiazepines. Most clinicians use a 2-4 week on, 1-2 week off structure and reassess at 90 days.
Selank Stacking: Protocols for Comprehensive Effect
Selank’s multi-system mechanism makes it highly stackable with other neuropeptides and metabolic therapies. The following combinations are used at Metabolic Regen MD based on specific patient presentations.
Selank + NAD+: Energy and Calm
NAD+ is foundational to mitochondrial energy production and neurotransmitter synthesis. In patients with anxiety layered over fatigue — a common pattern in burnout and post-viral recovery — the combination of Selank’s calming effect and NAD+’s energy restoration is particularly effective. Selank quiets the anxious nervous system while NAD+ restores the cellular energy needed for optimal brain function. [INTERNAL-LINK: nad-plus-therapy]
Selank + Semax: Balanced Cognitive Enhancement
As detailed above, Selank provides the calming anxiolytic foundation and Semax adds activating cognitive drive. This combination is best suited to patients who are not primarily anxiety-dominant but who want to optimize both stress resilience and mental performance. The typical approach is to administer Selank in the morning and Semax mid-morning, allowing each peptide’s onset to be staggered and monitored for individual response.
Selank + BPC-157: Gut-Brain Axis Anxiety
Emerging research confirms that gut inflammation and dysbiosis directly drive anxiety through the gut-brain axis via the vagus nerve and enteric nervous system. Patients with irritable bowel syndrome, leaky gut, or food sensitivities frequently present with anxiety as a secondary complaint. BPC-157 is a potent gut-healing peptide with demonstrated neurological effects, including upregulation of dopamine and serotonin receptors. Combining BPC-157’s gut-healing action with Selank’s direct anxiolytic and serotonergic effects addresses the anxiety problem at two levels simultaneously.
From our endocrinologist: “The gut-brain connection in anxiety is underappreciated in conventional psychiatry. I’ve had patients who didn’t respond well to SSRIs or anxiolytics alone make remarkable progress once we addressed the gut component with BPC-157 alongside Selank. It’s a paradigm that makes biological sense and matches what we see clinically.”
Safety Profile and Side Effects
Selank has a well-characterized safety profile based on two decades of Russian clinical use and published research. In clinical trials, side effects were generally mild and transient. The most commonly reported effects include brief nasal irritation with intranasal use, mild sedation in some patients (typically resolving after the first few days), and rare reports of headache or mild dizziness at higher doses.
No serious adverse events have been reported in published clinical trials. No dependence, withdrawal syndrome, or tolerance has been identified. Selank is not a controlled substance in the United States.
Selank should be used under physician supervision. It is not recommended during pregnancy or breastfeeding due to insufficient safety data. Patients on psychiatric medications should discuss potential interactions with their physician before starting any neuropeptide protocol.
Frequently Asked Questions
How quickly does Selank work for anxiety?
Intranasal Selank typically produces noticeable anxiolytic effects within 20-40 minutes of administration. This rapid onset distinguishes it from SSRIs, which require 4-8 weeks for full effect. Many patients report a calm, focused mental state beginning within the first hour of their first dose. The full clinical benefit across cognitive domains tends to build over 1-2 weeks of consistent use.
Is Selank addictive?
No dependence or addiction has been identified in clinical trials or post-market surveillance in Russia, where Selank has been a licensed pharmaceutical for over two decades. Unlike benzodiazepines, Selank does not bind directly to the benzodiazepine receptor site and does not produce the receptor downregulation that drives physical dependence. It is not a controlled substance in the United States ([Zozulya et al., CNS Drug Reviews, 2001, PMID: 11607046](https://pubmed.ncbi.nlm.nih.gov/11607046/)).
Can I take Selank while on an SSRI or other psychiatric medication?
This requires individual physician evaluation. Theoretically, combining Selank’s serotonergic effects with an SSRI could affect serotonin system activity. Some patients do use Selank as an adjunct to antidepressants under supervision, but this is a decision that requires a thorough medication review. Always disclose all medications to your prescribing physician before starting Selank.
What is the difference between Selank and Semax?
Selank is calming and anxiolytic: it reduces cortisol, modulates GABA, and quiets an overactivated nervous system. Semax is activating and stimulating: it increases dopamine, norepinephrine, and mental drive. Both improve BDNF and cognitive function, but from opposite neurological directions. Selank is the right choice for anxiety-dominant patients; Semax suits cognitive sluggishness and motivation deficits. The two can be combined carefully in appropriate patients.
How long should a Selank protocol last?
Most clinical protocols run 14-28 days, followed by a 1-2 week break before reassessment. Long-term strategies typically involve cycles of 4-6 weeks on, 2 weeks off, with periodic 90-day check-ins to evaluate response. Duration depends heavily on the indication — GAD management may require longer or recurring cycles, while cognitive optimization protocols may use shorter, targeted runs.
Conclusion: A New Paradigm for Anxiety and Cognitive Performance
Selank represents something genuinely uncommon in psychiatry and functional medicine: a compound that addresses anxiety without sacrificing cognitive performance. For decades, clinicians and patients have been forced to choose between anxiety control and mental sharpness. Benzodiazepines relieve anxiety but impair memory, attention, and reaction time. SSRIs take weeks to work and often blunt emotional range along the way.
Selank’s mechanism — modulating the GABAergic system, upregulating BDNF, stabilizing serotonin, and blunting cortisol — produces a clinical profile that is both anxiolytic and nootropic. The Russian clinical trial data, while not as large as Phase III Western trials, is more robust than the evidence base supporting many commonly used interventions. And two decades of pharmaceutical use in Russia provides a meaningful real-world safety signal.
At Metabolic Regen MD, Selank is one component of a broader neuro-metabolic approach that may include NAD+ therapy, peptide stacking, hormonal optimization, and lifestyle protocols — all supervised by our board-certified endocrinologist and tailored to each patient’s specific presentation and goals.
Elite Biologix supplies Selank at ≥98% purity, verified by third-party HPLC and mass spectrometry analysis, specifically for use in qualified research environments. View our Selank research compound.
Ready to explore whether Selank belongs in your protocol? Schedule your consultation with the Metabolic Regen MD team today and speak with our endocrinologist about a personalized approach to anxiety, stress, and cognitive performance.
References
- Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskiy II. Effects of Selank on anxiety disorders. Bulletin of Experimental Biology and Medicine. 2010;150(3):336-339. PMID: 20938582
- Kozlovskaya MM, Kozlovskiy II, Andreeva LA, Maklakova AS, Kryzhanovsky GN, Myasoedov NF. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Russian Journal of Bioorganic Chemistry. 2002;28(3):216-222. PMID: 12448595
- Zozulya AA, Neznamov GG, Teleshova ES, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Bulletin of Experimental Biology and Medicine. 2008;146(3):293-298. PMID: 19145313
- Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241-243. PMID: 18672612
- Filatova EV, Shimshirt AA, Myasoedov NF. Gene expression in brain tissues in rats under experimental anxiety-depressive syndrome corrected with Selank. Molecular Biology. 2012;46(3):476-482. PMID: 22642053
- Zozulya AA, Koshelev VB, Yudina MA, Voeikova AM, Zolotarev YA. Selank (heptapeptide) and tuftsin: dependence on naloxone and enkephalinase inhibitors. CNS Drug Reviews. 2001;7(2):203-219. PMID: 11607046
- Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37-48. PMID: 15370101
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21:133-146. PMID: 37268799
- Our World in Data / Global Burden of Disease Collaborative Network. Mental Health. 2018. ourworldindata.org/mental-health
- IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. 2023. iqvia.com
This article is for educational and informational purposes only. It does not constitute medical advice and is not a substitute for consultation with a licensed healthcare provider. All treatment protocols described are administered under physician supervision. Individual results will vary.
Ready to start?
Take the quiz, get matched by a licensed provider, and get shipped to your door.
Start now